Literature DB >> 22122271

A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine.

Mirte M Malingré1, Peggy C R Godschalk, Saskia K Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22122271      PMCID： PMC3394147          DOI： 10.1111/j.1365-2125.2011.04156.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

Review 1.  Therapeutic drug monitoring of voriconazole and posaconazole.

Authors:  Trana Hussaini; Maria J G T Rüping; Fedja Farowski; Janne J Vehreschild; Oliver A Cornely
Journal:  Pharmacotherapy       Date:  2011-02       Impact factor: 4.705

Review 2.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  Clinical importance of the CYP2C19*17 variant allele for voriconazole.

Authors:  Michael J Dolton; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

4.  Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.

Authors:  Arwa Hassan; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus; Walter E Haefeli; David Czock
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681
  4 in total
  7 in total

1.  High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.

Authors:  Youssef Bennis; Sandra Bodeau; Régis Bouquié; Guillaume Deslandes; Céline Verstuyft; Bérangère Gruson; Michel Andréjak; Anne-Sophie Lemaire-Hurtel; Taieb Chouaki
Journal:  Br J Clin Pharmacol       Date:  2015-08-24       Impact factor: 4.335

2.  Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.

Authors:  Pier Giorgio Cojutti; Maria Merelli; Lorenzo Allegri; Giuseppe Damante; Matteo Bassetti; Federico Pea
Journal:  Br J Clin Pharmacol       Date:  2018-11-09       Impact factor: 4.335

3.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

Review 4.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

5.  Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Authors:  J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

Review 6.  CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

Authors:  Aniwaa Owusu Obeng; Eric F Egelund; Abdullah Alsultan; Charles A Peloquin; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2014-02-07       Impact factor: 4.705

Review 7.  Drug-drug-gene interactions and adverse drug reactions.

Authors:  Mustafa Adnan Malki; Ewan Robert Pearson
Journal:  Pharmacogenomics J       Date:  2019-12-03       Impact factor: 3.550
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.